VU0463271 is a selective and potent antagonist of neuronal-specific potassium-chloride cotransporter 2 KCC2, with an IC50 of 61 nM. VU0463271 demonstrates over 100-fold selectivity compared to the closely related Na-K-2Cl cotransporter 1 (NKCC1).

BMS-911172 is a brain penetrant, selective inhibitor of adaptor protein 2-associated kinase 1 (AAK1) with an IC50 value of 12 nM. BMS-911172 inhibits μ2 phosphorylation and has potential as a therapeutic agent in neuropathic pain research.

BMS-911172 is a brain penetrant, selective inhibitor of adaptor protein 2-associated kinase 1 (AAK1) with an IC50 value of 12 nM. BMS-911172 inhibits μ2 phosphorylation and has potential as a therapeutic agent in neuropathic pain research.

BMS-911172 is a brain penetrant, selective inhibitor of adaptor protein 2-associated kinase 1 (AAK1) with an IC50 value of 12 nM. BMS-911172 inhibits μ2 phosphorylation and has potential as a therapeutic agent in neuropathic pain research.

BMS-911172 is a brain penetrant, selective inhibitor of adaptor protein 2-associated kinase 1 (AAK1) with an IC50 value of 12 nM. BMS-911172 inhibits μ2 phosphorylation and has potential as a therapeutic agent in neuropathic pain research.

BMS-509744 is a potent, selective and ATP competitive Itk inhibitor with an IC50 of 19 nM.

Elsubrutinib(ABBV-105) is a covalent, irreversible, potent, and highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 0.18 μM for BTK catalytic domain. It specifically inhibits BTK dependent cellular functions, including both BCR and FcγR mediated signaling. It also exhibits significant efficacy in pre-clinical mechanistic models of antibody production, as well as in […]

Elsubrutinib(ABBV-105) is a covalent, irreversible, potent, and highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 0.18 μM for BTK catalytic domain. It specifically inhibits BTK dependent cellular functions, including both BCR and FcγR mediated signaling. It also exhibits significant efficacy in pre-clinical mechanistic models of antibody production, as well as in […]

AZD8797 (KAND567) is an allosteric, non-competitive, and orally active antagonist of the human receptor CX3CR1. It antagonizes CX3CR1 with a Ki value of 3.9 nM, respectively. It effects G-protein signaling and β-arrestin recruitment.

Elsubrutinib(ABBV-105) is a covalent, irreversible, potent, and highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 0.18 μM for BTK catalytic domain. It specifically inhibits BTK dependent cellular functions, including both BCR and FcγR mediated signaling. It also exhibits significant efficacy in pre-clinical mechanistic models of antibody production, as well as in […]